1. Home
  2. IDYA vs HTGC Comparison

IDYA vs HTGC Comparison

Compare IDYA & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo IDEAYA Biosciences Inc.

IDYA

IDEAYA Biosciences Inc.

HOLD

Current Price

$38.85

Market Cap

3.6B

Sector

Health Care

ML Signal

HOLD

Logo Hercules Capital Inc.

HTGC

Hercules Capital Inc.

HOLD

Current Price

$17.46

Market Cap

3.2B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
IDYA
HTGC
Founded
2015
2003
Country
United States
United States
Employees
N/A
50
Industry
Biotechnology: Pharmaceutical Preparations
Investment Managers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
3.6B
3.2B
IPO Year
2019
2004

Fundamental Metrics

Financial Performance
Metric
IDYA
HTGC
Price
$38.85
$17.46
Analyst Decision
Strong Buy
Buy
Analyst Count
16
7
Target Price
$52.86
$18.86
AVG Volume (30 Days)
599.8K
1.3M
Earning Date
05-06-2026
05-05-2026
Dividend Yield
N/A
12.13%
EPS Growth
61.90
14.91
EPS
N/A
0.90
Revenue
$218,710,000.00
N/A
Revenue This Year
N/A
$11.18
Revenue Next Year
$201.05
$5.24
P/E Ratio
N/A
$19.30
Revenue Growth
3024.43
N/A
52 Week Low
$25.36
$13.70
52 Week High
$42.68
$19.25

Technical Indicators

Market Signals
Indicator
IDYA
HTGC
Relative Strength Index (RSI) 52.15 53.60
Support Level $35.11 $16.37
Resistance Level $40.58 $17.93
Average True Range (ATR) 1.13 0.28
MACD -0.21 -0.06
Stochastic Oscillator 36.51 31.71

Price Performance

Historical Comparison
IDYA
HTGC

About IDYA IDEAYA Biosciences Inc.

IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

About HTGC Hercules Capital Inc.

Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.

Share on Social Networks: